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Objective. To determine the association of plasma
B lymphocyte stimulator (BLyS) levels, immunosup-
pressive therapy, and other clinical parameters with
disease activity in systemic lupus erythematosus (SLE).
Methods. Two hundred forty-five SLE patients
were evaluated prospectively over a 2-year period at 4
centers. Assessments were performed every 3–6 months.
Univariate analysis was used to determine the associa-
tion among the Safety of Estrogens in Lupus Erythem-
atosus: National Assessment (SELENA) version of the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) score, serum anti–double-stranded DNA
(anti-dsDNA), and plasma BLyS levels. A multivariate
repeated-measures model incorporating immunosup-
pressive therapy was utilized.
Results. Ninety-two percent of the patients were
female. Sixty-seven percent were white, 31% African
American, and 2% Asian (all of these groups may
include Hispanic). Mean values at baseline were as
follows: age 41.5 years, disease duration 8.1 years,
SELENA–SLEDAI 3.3 (median 2, range 0–18), BLyS
5.57 ng/ml, IgG 1,439 mg/dl, C3 104.4 mg/dl, and C4 21.3
mg/dl; among those positive for anti-dsDNA, the median
titer was 1:40 (range 1:10–1:1,280). Univariate analysis
showed that plasma BLyS levels were associated with
anti-dsDNA titers (P  0.0465) and SELENA–SLEDAI
scores (P  0.0002). In multivariate analyses, a greater
increase in the SELENA–SLEDAI score from the previ-
ous visit was associated with higher BLyS levels at the
previous visit (P  0.0042) and with a greater increase
in the BLyS level from the previous visit (P  0.0007).
Conclusion. The findings of association between a
greater increase in the BLyS level from the previous
visit and a greater increase in the SELENA–SLEDAI
score at the subsequent visit, and between an elevated
BLyS level at the previous visit and a greater SELENA–
SLEDAI score at the subsequent visit, demonstrate a
relationship between circulating BLyS levels and SLE
disease activity. These results lend support to the notion
that BLyS is a candidate for therapeutic targeting in SLE.
B lymphocyte stimulator (BLyS; trademark of
Human Genome Sciences, Rockville, MD), also known
as BAFF (B cell–activating factor from the tumor ne-
crosis factor [TNF] family), is a type II transmembrane
protein (1). BLyS exists in both membrane-bound and
soluble forms and is expressed on monocytes, macro-
phages, and monocyte-derived dendritic cells. BLyS
gene expression and levels of membrane-associated sol-
uble BLyS are regulated by cytokines, in particular
interferon- and to a lesser extent interleukin-10 (2).
The biologically active soluble form of BLyS binds to 3
receptors expressed primarily on B lymphocytes: TACI
(TNF transmembrane activator and calcium modulator
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and cyclophilin ligand interactor), BCMA (B lympho-
cyte maturation antigen), and BR3 (BAFF/BLyS recep-
tor 3) (3,4). Activation of the BLyS receptors leads to B
cell and plasma cell proliferation, differentiation, and
survival and IgG class switching (1,5,6). A related TNF
family member, APRIL (a proliferation-inducing li-
gand), can also bind TACI and BCMA and can mediate
effects similar to those of BLyS, but its biologic action
may be primarily on memory plasma cells. BLyS–APRIL
heterotrimers have also been characterized (7), but their
function in vivo is unclear.
Circulating BLyS levels are elevated in patients
with systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), and other systemic immune-based rheu-
matic diseases. A correlation between plasma BLyS
protein levels and rheumatoid factor titers in patients
with RA has been reported (8,9). In addition, elevated
levels of BLyS have been detected in the synovial fluid of
patients with RA and have been correlated with levels of
autoantibodies associated with Sjögren’s syndrome (10).
In cross-sectional studies, 20–40% of patients with SLE
appear to have significantly higher levels of circulating
BLyS protein than are found in normal controls, and
plasma BLyS protein levels appear to correlate with IgG
levels and anti–double-stranded DNA (anti-dsDNA)
titers (8,9). In SLE and RA patients treated with ritux-
imab, BLyS levels increase with B cell depletion and
return to near-baseline levels upon B cell repopulation
(11,12).
Although the findings of elevated levels of BLyS
protein in autoimmune diseases suggest that BLyS may
be a marker of current or impending autoimmune
disease activity and may be a potential target for thera-
peutic intervention, the relationship between circulating
BLyS levels and SLE disease activity has not been
adequately characterized. Accordingly, this 2-year obser-
vational study was designed to assess the relationships
between plasma BLyS concentrations and disease activ-
ity, autoantibody and immunoglobulin levels, and treat-
ments received for SLE.
PATIENTS AND METHODS
Patients and study design. This 2-year multicenter
observational study was undertaken to assess disease activity,
therapies, and multiple biomarkers including plasma BLyS
levels in patients with SLE as defined by the American College
of Rheumatology (ACR) classification criteria (13,14). Pa-
tients received standard-of-care therapy for their disease. To
be eligible for the study, patients had to be at least 18 years old
and could not have been treated with an investigational agent
within 28 days prior to the start of the study. None of the study
patients were found to have received an investigational agent
at any time. Originally designed as a single-year natural history
investigation, the study was extended to measure BLyS and
evaluate disease activity through a second year. Patients were
assessed clinically, and blood and urine samples were collected
every 3 months during the first year of the study and every 6
months during the second year. Patients were also assessed during
any unscheduled clinical visits that were necessary due to acute
exacerbation of SLE disease activity. Written informed con-
sent was obtained from all study patients prior to enrollment.
Patient assessment. At baseline, the medical history
was reviewed and information on current medications and on
the components of the ACR SLE classification criteria that the
patient fulfilled was recorded. To assess disease activity, the
Safety of Estrogens in Lupus Erythematosus: National Assess-
ment (SELENA) version of the Systemic Lupus Erythemato-
sus Disease Activity Index (SLEDAI) (15,16) was adminis-
tered, and plasma BLyS, C3/C4, and anti-dsDNA
autoantibodies measured, at baseline, at 3, 6, 9, 12, 18, and 24
months, and at any unscheduled visits. Total immunoglobulins
and subclasses (IgM, IgA, IgG, and IgE) were measured at
baseline and at the 6-, 12-, 18-, and 24-month scheduled visits.
A complete blood cell count and urinalysis were performed at
baseline, at 3, 6, 9, 12, 18, and 24 months, and at any
unscheduled visit.
To measure plasma BLyS levels, 10 ml of blood was
collected in Vacutainer tubes containing EDTA, centrifuged
for 15 minutes at 1,500 revolutions per minute, aliquoted (0.5
ml) into cryotubes, and immediately frozen at –70°C. Plasma
BLyS levels were measured by enzyme-linked immunosorbent
assay (ELISA) with mouse anti-human BLyS monoclonal
antibody 3D4 as the capture antibody and biotinylated rabbit
anti-human BLyS polyclonal antibody as the detector antibody.
Recombinant soluble BLyS was used to standardize the assay
(interassay variability 15%) (17). The normal plasma BLyS
level measured using this assay ranged from 1 ng/ml to 5 ng/ml
in healthy adults. The BLyS assay was performed at Human
Genome Sciences Laboratory. Serum levels of biologic mark-
ers, including anti-dsDNA, total immunoglobulin, and immu-
noglobulin subclasses, were also measured by ELISA.
Statistical analysis. Disease history, use of immuno-
suppressive agents, and baseline demographic characteristics
were compared among study sites (see below). These compar-
isons were performed using the likelihood ratio test for
discrete variables and analysis of variance (ANOVA) or Wil-
coxon’s rank sum test, as appropriate, for continuous variables.
Descriptive statistics were used to summarize demo-
graphic and baseline disease characteristics, as well as changes
in BLyS levels over time. Univariate association analysis
was used to analyze BLyS levels and other variables, such as
SELENA–SLEDAI scores and immunoglobulin levels. The
significance of differences in BLyS levels between patients with
and those without detectable anti-dsDNA antibodies was
assessed by Student’s t-test.
A repeated-measures analysis of covariance model was
used to examine the relationship between disease activity and
BLyS level, immunosuppressive drug use, and steroid dosage.
In this model, the dependent variable was the change in
SELENA–SLEDAI score from the previous to the current
visit, and the explanatory variables were 1) BLyS level at the
previous visit, 2) change in BLyS level from the previous to the
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current visit, 3) whether the patient was receiving prednisone
in the last 3 months, 4) change in the prednisone dosage from
the previous to the current visit, 5) whether the patient was
receiving immunosuppressive treatment in the last 3 months,
and 6) SELENA–SLEDAI score at the previous visit. The
model was also adjusted for study site, the patient’s race (white
versus other), the interaction effect between study site and
race, and age. A spatial covariance structure was assumed to
account for the correlation between repeated observations
within each patient.
RESULTS
Demographic and baseline clinical characteris-
tics of the patients. A total of 245 patients at 4 clinical
centers (Johns Hopkins University, University of South-
ern California, University of Alabama at Birmingham,
and University of Michigan) were enrolled in this obser-
vational study. Patient demographic characteristics,
baseline disease characteristics, and ACR classification
criteria by clinical center are summarized in Table 1.
Approximately 90% of the patients at each clinical
center were female. The mean age was 41.5 years. The
majority of the patients were white (ethnicity was self-
reported, with 67% white, 31% African American, and
2% Asian [all of these ethnicity categories could include
subjects of Hispanic origin]).
The mean duration of SLE was 8.1 years, and the
mean baseline SELENA–SLEDAI score was 3.3 (me-
dian 2, range 0–18). The SLE study population was












Female 90 (90) 65 (94) 47 (94) 24 (92)
Male 10 (10) 4 (6) 3 (6) 2 (8)
Race‡ 0.001
White 51 (51) 62 (90)§ 27 (54) 23 (88)
African American 47 (47) 4 (6) 23 (46) 3 (12)
Asian 2 (2) 3 (4) 0 0
Age, mean  SD years 43  12 41  13 39  11 43  15 0.372
Duration of SLE, mean  SD years 8.8  7.7 8.7  9.3 4.6  4.7 11.0  9.7 0.003
SELENA–SLEDAI score 0.001
Median 2.0 4.0 4.0 2.0
Mean  SD 2.0  2.4 4.7  4.5 4.3  3.6 3.1  3.0
Prednisone use 53 (53) 58 (84) 35 (70) 19 (73) 0.0002
Prednisone dosage, median (range) mg/day 7.5 (1–140) 10 (1–40) 10 (2.5–20) 5 (1–15) 0.0200
Immunosuppressive drug use¶
Azathioprine 7 (7) 36 (52.2) 14 (28) 2 (7.7) 0.0001
Mycophenolate mofetil 15 (15) 3 (4.3) 0 12 (46.2) 0.0001
Cyclophosphamide 13 (13) 4 (5.8) 2 (4) 0 0.1013
Methotrexate 9 (9) 5 (7.2) 11 (22) 4 (15.4) 0.0787
Hydroxychloroquine 63 (63) 59 (86) 37 (74) 19 (73) 0.0149
Components of SLE
ANA positive 97 (97) 63 (91) 49 (98) 25 (96) 0.290
Arthritis 62 (62) 50 (72) 41 (82) 21 (81) 0.039
Malar rash 50 (50) 30 (43) 28 (56) 12 (46) 0.583
Photosensitivity 48 (48) 30 (43) 24 (48) 14 (54) 0.830
Immunologic 39 (39) 40 (58) 19 (38) 14 (54) 0.048
Hematologic 49 (49) 30 (43) 16 (32) 11 (42) 0.261
Oral ulcers 42 (42) 17 (25) 25 (50) 6 (23) 0.009
Renal 28 (28) 31 (45) 11 (22) 9 (35) 0.040
Serositis 26 (26) 19 (28) 8 (16) 5 (19) 0.404
Discoid rash 18 (18) 5 (7) 5 (10) 5 (19) 0.137
Neurologic 7 (7) 2 (3) 0 2 (8) 0.077
* Except where indicated otherwise, values are the number (%). JHU  Johns Hopkins University; USC  University of Southern California;
UAB  University of Alabama at Birmingham; UM  University of Michigan; SLE  systemic lupus erythematosus; SELENA–SLEDAI  Safety
of Estrogens in Lupus Erythematosus: National Assessment version of the SLE Disease Activity Index; ANA  antinuclear antibody.
† Significance of the difference among sites, by analysis of variance, Wilcoxon’s rank sum test, or likelihood ratio test.
‡ All race categories may include patients of Hispanic origin.
§ Majority were Hispanic.
¶ One patient took cyclosporin A during the study. No patients took biologic agents.
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observed to be heterogeneous as indicated by statisti-
cally significant differences in race distribution, duration
of SLE, and baseline SELENA–SLEDAI scores across
the 4 clinical centers. Based on historical record review
or assessment at the baseline study visit, nearly all of the
patients (96%) were antinuclear antibody positive, and
71% had arthritis. Overall, malar rash, photosensitivity,
immunologic disorders, and hematologic disorders were
each reported in approximately half of the patients. The
incidences of arthritis, immunologic disorders, oral ul-
cers, and renal disorders were significantly different
among the 4 study sites (P  0.05). The use of cortico-
steroids and immunosuppressive drugs also differed
significantly across sites (Table 1).
Levels of BLyS, immunoglobulin subgroups, and
anti-dsDNA were assessed at baseline (Table 2). The
mean baseline plasma level of BLyS in all patients
combined was 5.57 ng/ml (range 1.5–19.1). At baseline,
BLyS levels were positively correlated with SELENA–
SLEDAI scores (P  0.057) and IgG levels (P  0.008).
In addition, BLyS levels were significantly higher among
patients with detectable anti-dsDNA antibodies (P 
0.017) (Figure 1).
BLyS levels and relationship to SLE disease
activity. Eighty-eight percent of the patients exhibited a
25% change from baseline in the plasma BLyS level,
on at least 1 clinical visit. Plasma BLyS levels varied over
time during the 2 years of observation, with 55% of the
patients exhibiting a 50% increase or decrease at any 1
(or more) clinical visit compared with baseline.
Association analyses (Figure 2) showed that anti-
dsDNA levels were positively associated with BLyS
concentrations (P  0.0127) and with the SELENA–
SLEDAI score (P  0.0003) across all visits. BLyS levels
at the current visit correlated with the SELENA–
SLEDAI score (P  0.0002), and an elevated BLyS level
at the previous visit predicted anti-dsDNA positivity
(P  0.0465). On average, patients with BLyS levels of
Figure 1. Levels of B lymphocyte stimulator (BLyS) in relation to
anti–double-stranded DNA (anti-dsDNA) status (as determined by
immunofluorescence assay) in the systemic lupus erythematosus pa-
tients at each study visit. Values are the mean and SEM.
Figure 2. Associations between systemic lupus erythematosus (SLE)
disease activity, presence of anti-dsDNA, and BLyS level. Score on the
Safety of Estrogens in Lupus Erythematosus: National Assessment
(SELENA) version of the SLE Disease Activity Index (SLEDAI) was
positively associated with BLyS concentration and with the presence of
anti-dsDNA. Anti-dsDNA level was positively associated with BLyS
concentration and SELENA–SLEDAI score. BLyS level at the current
visit associated with SELENA–SLEDAI score. BLyS level at the
previous visit predicted presence of anti-dsDNA at the current visit.
The direction of each arrow indicates the independent variable
(predictor) and the outcome variable (e.g., the P value of 0.0127 on the
arrow pointing from anti-dsDNA to BLyS means that the anti-dsDNA
level significantly predicts the level of BLyS).   independent variable
was the BLyS level at the previous visit (all other variables refer to the
current visit). See Figure 1 for other definitions.
Table 2. Baseline levels of BLyS, immunoglobulin subgroups, and
anti-dsDNA*
Parameter Mean Median Range
BLyS, ng/ml (normal 1–5) 5.57 4.85 1.5–9.1
Immunoglobulin subgroup†
IgG, mg/dl (normal 694–1,618) 1,439 1,325 461–5,180
IgA, mg/dl (normal 84–463) 303 279 0–1,110
IgM, mg/dl (normal 48–291) 132 116 3–708
Anti-dsDNA, titer (by IF)
(normal 1:30)‡
NA 1:40 1:10–1:1,280
C3, mg/dl 104.4 99 24.5–189
C4, mg/dl 21.3 20 0–145
* Values are for patients from all study sites combined. BLyS  B
lymphocyte stimulator; anti-dsDNA  anti–double-stranded DNA;
NA  not appropriate.
† Normal ranges from Quest Diagnostics (Van Nuys, CA). Thirty-nine
percent of the patients had IgG levels 1,500 mg/dl, 16% had IgA
levels 460 mg/dl, and 6% had IgM levels 270 mg/dl.
‡ Only 60 patients (24%) had detectable levels (1:10) by immuno-
fluorescence (IF) assay.
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10 ng/ml had 2-point higher SELENA–SLEDAI
scores than those with BLyS levels of 10 ng/ml.
A multivariate analysis was performed to investi-
gate the relationship between the change in the
SELENA–SLEDAI scores from the previous visit and
BLyS levels, with adjustment for immunosuppressive
drug treatment and changes in prednisone use since the
last visit, SELENA–SLEDAI score at the previous visit,
and baseline demographic characteristics (Table 3). The
model showed that changes in the SELENA–SLEDAI
score from the previous visit were significantly and
positively associated with the BLyS level at the previous
visit and with the change in the BLyS level from the
previous to the current visit. There was a trend toward
greater increases in the SELENA–SLEDAI score at the
current visit among patients who had higher BLyS levels
at the previous visit and among those with greater
increases in BLyS levels from the previous to the current
visit.
Analysis using a multivariate repeated-measures
ANOVA model with adjustment for the effects of
arthritis, immunologic disorders, oral ulcers, and renal
disorders showed the same significant effects of both
BLyS level at the previous visit (P  0.004) and change
in BLyS level from the previous visit to the current visit
(P  0.0007). The study center effect also remained
similar. The results also showed that patients with oral
ulcers at the time of diagnosis were significantly more
likely to have an increase in disease activity (P 
0.0075).
To assess the effect of the differences in fre-
quency of data collection between year 1 and year 2, an
analysis using the multivariate repeated-measures model
was performed. The results showed the same significant
effects of both BLyS level at the previous visit (P 
0.0034) and changes in BLyS level from the previous visit
to the current visit (P  0.0006). The effect of the
different schedules for data collection was not statisti-
cally significant (P  0.4619).
To evaluate the relationship between changes in
BLyS level and development of a mild-to-moderate SLE
flare (18) or improvement in SLE disease activity (19),
BLyS levels were correlated with the percentage of
patients who had an increase of 3 points in the
SELENA–SLEDAI score from the previous visit to the
current visit, and with the percentage who had a reduc-
tion of 4 points in the SELENA–SLEDAI score from
the previous visit to the current visit. Univariate analysis
showed that the increase in BLyS level from the previous
visit to the current visit appeared to be associated with








BLyS level at previous visit Positive 0.096 (0.033) 0.0042
Change in BLyS level from previous to
current visit
Positive 0.121 (0.035) 0.0007
SELENA–SLEDAI score at previous visit Negative 0.639 (0.028) 0.0001
Race effect (nonwhite), within site
JHU Negative 2.590 (1.102) 0.0196
USC Negative 1.133 (0.639) 0.0774
UAB Negative 0.141 (0.353) 0.6907
UM Positive 0.540 (0.271) 0.0478
Prednisone use in last 3 months Positive 0.405 (0.200) 0.0520
Prednisone dosage change from last visit Negative 0.002 (0.010) 0.8168
Immunosuppressive drug use in last 3 months Positive 0.358 (0.194) 0.0793
Age Negative 0.010 (0.007) 0.1648
* Analysis was performed using a repeated-measures analysis of covariance model. See Table 1 for other
definitions.
† When C4 level and presence of anti–double-stranded DNA at the current visit were added to the model,
the effect of change in B lymphocyte stimulator (BLyS) level from the previous visit to the current visit and
the effect of SELENA–SLEDAI score at the previous visit remained significant, and the effect of BLyS
level at the previous visit was marginally significant (P  0.0798).
‡ Parameter estimates indicate the increase in SELENA–SLEDAI score for each 1-unit increase in the
given predictor (continuous variables) or the increase in SELENA–SLEDAI score associated with being
in the category of the given predictor compared with not being in the category (for categorical variables)
(e.g., for change in BLyS level from previous to current visit, the SELENA–SLEDAI score would increase
an average of 0.121 points for each 1 ng/ml increase in the BLyS level from the previous visit to the current
visit).
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the occurrence of mild-to-moderate flares (P  0.0512).
In the subgroup of patients with SELENA–SLEDAI
scores of 4, improvement of 4 points in the
SELENA–SLEDAI score from the previous visit to the
current visit was more likely to be observed among those
who had a 1 ng/ml reduction in the BLyS level from
the previous visit to the current visit with a BLyS level
that was within the normal range (1–5 ng/ml) at the
current visit. Twenty percent of these patients exhibited
improvement of 4 points in the SELENA–SLEDAI
score, whereas only 10% of the patients with significant
increases in the BLyS level (increases of 1 ng/ml, from
within the normal range to 5 ng/ml) showed improve-
ment of 4 points in the SELENA–SLEDAI score (P 
0.0495).
DISCUSSION
Several reports have suggested a central role of
BLyS in the pathogenesis of SLE (3,5,20). Transgenic
mice that overexpress BLyS have an increased number
of B cells, enlarged lymphoid organs, and hypergamma-
globulinemia, and express symptoms that resemble SLE
(5,20). In addition, the constitutive overexpression of
BLyS in these animals is associated with antinuclear and
anti-dsDNA antibodies. Elevated levels of BLyS have
been found in other murine models of SLE, including
MRL-lpr/lpr and (NZB  NZW)F1 strains. It has been
shown that treatment of mice overexpressing BLyS with
a BLyS receptor fusion protein ameliorates the progres-
sion of SLE and improves survival (3). In SLE patients
with B cell depletion, BLyS levels increase until B cell
repopulation occurs (11).
Given the apparent link between BLyS and auto-
immune disease pathogenesis in animal studies, in this
prospective study we tracked BLyS levels, clinical dis-
ease activity, and biologic markers, and accounted for
changes in therapy. Our study cohort should be broadly
generalizable, in that it incorporates observations at 4
clinical centers with differences in patient ethnicity and
medications. BLyS levels predicted increases in SLE
disease activity across all study sites, supporting the
notion that elevated BLyS has a role as a biomarker for
current and/or future SLE disease activity. This obser-
vation was consistent when differences in disease mani-
festations, immunosuppressive drug treatment, study
site, and race distribution were addressed in the model.
The results of this study should be contrasted
with findings of past investigations. In one longitudinal
cohort, SLE patients exhibited heterogeneity, with 50%
manifesting persistently or intermittently elevated
plasma BLyS levels and 61% manifesting persistently or
intermittently elevated blood BLyS messenger RNA
(mRNA) phenotypes (17). In another study, changes in
SLEDAI scores were more closely associated with
changes in BLyS mRNA levels than with changes in
BLyS protein levels (21).
It is important to note that the findings in the
present study are based on measurement of BLyS levels
in plasma. Glomerulonephritis may increase BLyS ex-
cretion in the urine, thereby resulting in lower plasma
BLyS levels when renal disease contributes to the
SELENA–SLEDAI score. Future analyses of urine
BLyS protein and local production of BLyS (e.g., in
lymphatic tissues and joints) may prove to be highly
informative.
The apparent role of increased BLyS in SLE
disease activity suggests that an anti-BLyS therapeutic
approach may prove useful in controlling disease activity
and progression. If disease activity is driven in part by a
failure of dysregulated B cells to undergo apoptosis,
targeting of BLyS signaling may afford the opportunity
to specifically reduce pathogenic B cell responses while
maintaining sufficient B cell activity to preserve normal
immune function (22).
Multivariate analyses in this observational study
have shown that use of immunosuppressive therapy is
positively associated with disease activity and with BLyS
level at the current and previous visits. Decreases in
BLyS levels were associated with improvement in SLE
disease activity (19), whereas increases in BLyS levels
were associated with worsening of SLE disease activity
indicative of mild-to-moderate flare (18). BLyS concen-
trations appear to be associated with current and future
disease activity in patients with SLE, as measured by the
SELENA–SLEDAI, and this finding supports the ration-
ale for investigation of BLyS antagonism as a potential
therapeutic approach in SLE.
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